SCHEMBL26345706

SCHEMBL26345706

CNc1cc(C(C)C)ccc1C(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.39
▸ TRPA1 O75762 2/20 0.38
▸ PTGS1 P23219 1/20 0.38
▸ CACNA1C Q13936 1/20 0.38
▸ GAA P10253 2/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ ALOX12 P18054 1/20 0.36
▸ HTT P42858 1/20 0.36
▸ HIF1A Q16665 1/20 0.36
▸ RNASEH1 O60930 1/20 0.34
▸ MAPT P10636 2/20 0.33
▸ MEN1 O00255 2/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ GABRA1 P14867 1/20 0.33
▸ GABRB2 P47870 1/20 0.33
▸ TYR P14679 1/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ CHRM1 P11229 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20987638 0.78 LMNA (0.54) LMNATRPA1PTGS1CACNA1CGAA
SCHEMBL14200412 0.78 LMNA (0.35) LMNATRPA1PTGS1CACNA1CGAA
SCHEMBL24869039 0.77 RECQL (0.44) LMNATRPA1L3MBTL1CHRM1SLC6A2
SCHEMBL22537648 0.77 LMNA (0.38) LMNATRPA1PTGS1CACNA1CGAA
SCHEMBL14044154 0.77 LMNA (0.38) LMNATRPA1PTGS1CACNA1CGAA
SCHEMBL11795645 0.75 GAA (0.47) LMNAGAAMAPTMEN1KMT2A
SCHEMBL21023213 0.74 LMNA (0.48) LMNATRPA1PTGS1CACNA1CGAA
SCHEMBL29630154 0.74 LMNA (0.46) LMNATRPA1PTGS1CACNA1CGAA
SCHEMBL778017 0.74 LMNA (0.46) LMNATRPA1PTGS1CACNA1CGAA
SCHEMBL20987666 0.74 MEN1 (0.49) LMNAGAAALDH1A1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230339937-A1 CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS SATO PHARMACEUTICAL CO., LTD. (JP) 2023-10-26 — — US disclosed
US-20230295146-A1 INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES 1 AND 4 THE UNIVERSITY OF ROCHESTER 2023-09-21 — — US disclosed
US-20230295146-A1 INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES 1 AND 4 THE UNIVERSITY OF ROCHESTER 2023-09-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295146-A1 INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES 1 AND 4 IRAK4, IRAK1, IRAK2 LMNA 4068/4885TRPA1 1940/4885PTGS1 1005/4885
US-20230339937-A1 CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS HPGDS, PTGS1, PTGIS LMNA 1917/4885TRPA1 2044/4885PTGS1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback